2024
Cohort study of patients with advanced cancer: outcomes associated with duration of antibiotic therapy for non-ventilator hospital-acquired pneumonia
Lee S, Benson J, Cohen A, Quagliarello V, Juthani-Mehta M, Datta R. Cohort study of patients with advanced cancer: outcomes associated with duration of antibiotic therapy for non-ventilator hospital-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology 2024, 4: e48. PMID: 38655023, PMCID: PMC11036428, DOI: 10.1017/ash.2024.54.Peer-Reviewed Original ResearchNon-ventilator hospital-acquired pneumoniaAdvanced cancerPalliative care settingHospital-acquired pneumoniaCohort study of patientsCare settingsOlder adultsAdjusted oddsDuration of antibiotic therapyAssociated with reduced adjusted oddsSingle-center observational studyCohort studyProlonged antibiotic durationObservational studyStudy of patientsAntimicrobial stewardship effortsAntibiotic durationAntibiotic therapyStewardship effortsPneumoniaCancerOddsReadmissionAdultsCohortDaily Toothbrushing to Prevent Hospital-Acquired Pneumonia—Brushing Away the Risk
Datta R. Daily Toothbrushing to Prevent Hospital-Acquired Pneumonia—Brushing Away the Risk. JAMA Internal Medicine 2024, 184: 142-143. PMID: 38109108, DOI: 10.1001/jamainternmed.2023.6807.Peer-Reviewed Original ResearchDiagnostic uncertainty and decision‐making in home‐based primary care: A qualitative study of antibiotic prescribing
Datta R, Kiwak E, Fried T, Benjamin A, Iannone L, Krein S, Carter W, Cohen A. Diagnostic uncertainty and decision‐making in home‐based primary care: A qualitative study of antibiotic prescribing. Journal Of The American Geriatrics Society 2024, 72: 1468-1475. PMID: 38241465, PMCID: PMC11090732, DOI: 10.1111/jgs.18778.Peer-Reviewed Original ResearchHome-based primary carePrimary carePromote antibiotic stewardshipHome-based primary care programAntibiotic decision-makingPrimary care programsHome care settingPerspectives of cliniciansConstant comparative methodSemi-structured interviewsDeliver medical careHomebound patientsCare settingsCare programDiagnostic uncertaintyYears of experienceTheoretical saturationMedical careQualitative studyDecision-makingAntibiotic prescribingCareGrounded theoryAntibiotic stewardshipPrescribing
2023
Frontiers in antimicrobial stewardship: antimicrobial use during end-of-life care
Lee S, Datta R. Frontiers in antimicrobial stewardship: antimicrobial use during end-of-life care. Antimicrobial Stewardship & Healthcare Epidemiology 2023, 3: e164. PMID: 38028928, PMCID: PMC10644156, DOI: 10.1017/ash.2023.207.Peer-Reviewed Original ResearchCareer development in pragmatic clinical trials to improve care for people living with dementia
Gabbard J, Sadarangani T, Datta R, Fabius C, Gettel C, Douglas N, Juckett L, Kiselica A, Murali K, McCarthy E, Torke A, Callahan C. Career development in pragmatic clinical trials to improve care for people living with dementia. Journal Of The American Geriatrics Society 2023, 71: 3554-3565. PMID: 37736669, PMCID: PMC10810339, DOI: 10.1111/jgs.18599.Peer-Reviewed Original ResearchAn AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model
Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan W, Davidson E, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder E, Coppi A, Schulz W, Iwasaki A, Pierce R, Cruz C, Desir G, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis N, Ko A, Thompson D, Vasiliou V. An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model. Human Genomics 2023, 17: 80. PMID: 37641126, PMCID: PMC10463861, DOI: 10.1186/s40246-023-00521-4.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsDisease severityViral outbreaksFuture viral outbreaksLength of hospitalizationIntensive care unitWorse disease prognosisLife-threatening illnessEffective medical interventionsCOVID-19Clinical decision treeGlucuronic acid metabolitesNew potential biomarkersHospitalization lengthCare unitComorbidity dataSerotonin levelsDisease progressionHealthy controlsPatient outcomesDisease prognosisPatient transferPatientsHealthcare resourcesPotential biomarkersAntimicrobial resistance in Escherichia coli and Klebsiella pneumoniae urine isolates from a national sample of home-based primary care patients with dementia
Datta R, Pirruccio G, Fried T, O’Leary J, Zullo A, Cohen A. Antimicrobial resistance in Escherichia coli and Klebsiella pneumoniae urine isolates from a national sample of home-based primary care patients with dementia. Infection Control And Hospital Epidemiology 2023, 44: 1873-1876. PMID: 37211919, PMCID: PMC10663380, DOI: 10.1017/ice.2023.98.Peer-Reviewed Original ResearchAntibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study
Datta R, Han L, Doyle M, Allore H, Sanft T, Quagliarello V, Juthani-Mehta M. Antibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study. Palliative Medicine 2023, 37: 793-798. PMID: 36999898, DOI: 10.1177/02692163231162889.Peer-Reviewed Original ResearchConceptsAdverse drug eventsAntibiotic therapyDrug eventsAdvanced cancerOlder adultsIndex admissionPalliative chemotherapyCohort studyTertiary care centerHospitalized older adultsPalliative care providersMultidrug-resistant organismsMean ageCommon tumorsCare centerCare providersRatio of daysSolid tumorsMultivariable testingPatientsTherapyStandardized criteriaCancerMean timeAdultsNonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19
Cohen A, Glick L, Lee S, Kunitomo Y, Tsang D, Pitafi S, Toro P, Ristic N, Zhang E, Carey G, Datta R, Dela Cruz C, Gautam S. Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19. European Clinical Respiratory Journal 2023, 10: 2174640. PMID: 36815942, PMCID: PMC9930745, DOI: 10.1080/20018525.2023.2174640.Peer-Reviewed Original ResearchSevere COVID-19Bacterial superinfectionBacterial pneumoniaCOVID-19Lower respiratory culturesSuperimposed bacterial pneumoniaUtility of procalcitoninProcalcitonin measurementImmune biomarkersClinical resemblanceRespiratory culturesImmunomodulatory agentsProcalcitoninPatientsBacterial infectionsSuperinfectionCurve analysisSignificant riskCharacteristic curvePneumoniaTime of cultureDiagnosisInfectionBiomarkersClinicians who primarily practice in nursing homes and outcomes among residents with urinary tract infection or pneumonia
Riester M, Douglas C, Silva J, Datta R, Zullo A. Clinicians who primarily practice in nursing homes and outcomes among residents with urinary tract infection or pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology 2023, 3: e253. PMID: 38178878, PMCID: PMC10762639, DOI: 10.1017/ash.2023.527.Peer-Reviewed Original ResearchUrinary tract infectionNursing homesNH residentsTract infectionsAntibiotic dispensingLower riskGreater riskInfection-related outcomesAdjusted risk ratioMinimum Data Set dataPrimary practice settingPoisson regression modelsU.S. nursing homesPneumonia groupUTI groupRetrospective cohortRisk ratioStudy populationSimilar riskClinician trainingMedicare feeService claimsPneumoniaResident outcomesPractice settings
2022
Prevalence and treatment of postobstructive pneumonia among older adults with advanced cancer
Lee S, O’Donovan L, Cohen A, Gautam S, Quagliarello V, Juthani-Mehta M, Datta R. Prevalence and treatment of postobstructive pneumonia among older adults with advanced cancer. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e152. PMID: 36483405, PMCID: PMC9726473, DOI: 10.1017/ash.2022.293.Peer-Reviewed Original ResearchNational Cohort Study of Homebound Persons Living With Dementia: Antibiotic Prescribing Trends and Opportunities for Antibiotic Stewardship
Datta R, Fried T, O’Leary J, Zullo AR, Allore H, Han L, Juthani-Mehta M, Cohen A. National Cohort Study of Homebound Persons Living With Dementia: Antibiotic Prescribing Trends and Opportunities for Antibiotic Stewardship. Open Forum Infectious Diseases 2022, 9: ofac453. PMID: 36147594, PMCID: PMC9487603, DOI: 10.1093/ofid/ofac453.Peer-Reviewed Original ResearchHome-based primary careDays of therapyAntibiotic use ratesAntibiotic useHomebound personsOverall median lengthPhysician home visitsNational cohort studyAntibiotic prescribing trendsVeterans Health AdministrationUse ratesProvider visitsAntibiotic prescriptionsCohort studyPrescribing trendsTelephone visitsMedian agePrescription fillsMedian lengthAntibiotic stewardshipNational cohortPrimary careHome visitsHealth AdministrationPrescribed classClinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
Tuan J, Kayani J, Fisher A, Kotansky B, Dembry L, Datta R. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e83. PMID: 36483361, PMCID: PMC9726471, DOI: 10.1017/ash.2022.229.Peer-Reviewed Original ResearchDalbavancin administrationOutpatient parenteral antimicrobial therapyDose of dalbavancinMedian antibiotic durationSoft tissue infectionsParenteral antimicrobial therapyAntibiotic durationDeveloped hepatotoxicityClinical cureSeptic arthritisClinical outcomesAntimicrobial therapyPatientsAdministrationDaysEndocarditisArthritisBacteremiaOsteomyelitisHepatotoxicityTherapyDalbavancinInfectionDoseComparison of traditional instruction versus nontraditional learning to improve trainee knowledge of urine culture practices in catheterized patients
Gao CA, Datta R, Dunne D, Dembry LM, Martinello RA, Juthani-Mehta M, Advani SD. Comparison of traditional instruction versus nontraditional learning to improve trainee knowledge of urine culture practices in catheterized patients. Antimicrobial Stewardship & Healthcare Epidemiology 2022, 2: e81. PMID: 35647610, PMCID: PMC9139028, DOI: 10.1017/ash.2022.225.Peer-Reviewed Original ResearchSubcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich MD, Shah NR, Taylor TH, Page ST, Schiller SJ, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach PA. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLOS ONE 2022, 17: e0263591. PMID: 35213547, PMCID: PMC8880885, DOI: 10.1371/journal.pone.0263591.Peer-Reviewed Original ResearchConceptsStandard of careSubcutaneous sarilumabMechanical ventilationSevere COVID-19 diseaseHospitalized COVID-19 patientsDays of randomizationIL-6R inhibitionRate of intubationTrial of patientsSevere COVID-19COVID-19 patientsNumber of patientsVA Medical CenterAnti-inflammatory drugsCOVID-19SARS-CoV-2COVID-19 diseaseData monitoring committeeEligible patientsPrimary endpointSOC armPrimary outcomeRespiratory compromiseElectronic health record systemsClinical criteria
2021
517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich M, Shah N, Taylor T, Page S, Schiller S, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach P. 517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial. Open Forum Infectious Diseases 2021, 8: 360-360. PMCID: PMC8690689, DOI: 10.1093/ofid/ofab466.716.Peer-Reviewed Original ResearchSubcutaneous sarilumabStandard careMechanical ventilationLearning healthcare systemClinical trialsSevere COVID-19 diseaseCOVID-19Rate of intubationSevere COVID-19Trial of patientsCare clinical trialsIL-6 inhibitionTreatment of patientsNumber of patientsStandard of careHealthcare systemEvidence of benefitCOVID-19 diseaseData monitoring committeeA PragmaticPrimary endpointChart reviewHospitalized patientsPrimary outcomeSupplemental oxygenSurveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness
Datta R, Barrett A, Burk M, Salone C, Au A, Cunningham F, Fisher A, Dembry LM, Akgün KM. Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness. Infection Control And Hospital Epidemiology 2021, 43: 1488-1491. PMID: 33985598, PMCID: PMC8160489, DOI: 10.1017/ice.2021.227.Peer-Reviewed Original ResearchIncreasing face-mask compliance among healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic
Datta R, Glenn K, Pellegrino A, Tuan J, Linde B, Kayani J, Patel K, Calo L, Dembry LM, Fisher A. Increasing face-mask compliance among healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. Infection Control And Hospital Epidemiology 2021, 43: 616-622. PMID: 33938417, PMCID: PMC8144836, DOI: 10.1017/ice.2021.205.Peer-Reviewed Original ResearchStability of SARS-CoV-2 RNA in Nonsupplemented Saliva - Volume 27, Number 4—April 2021 - Emerging Infectious Diseases journal - CDC
Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF, Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M, Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL, . Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva - Volume 27, Number 4—April 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 1146-1150. PMID: 33754989, PMCID: PMC8007305, DOI: 10.3201/eid2704.204199.Peer-Reviewed Original ResearchIncreased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples - Volume 27, Number 4—April 2021 - Emerging Infectious Diseases journal - CDC
Watkins AE, Fenichel EP, Weinberger DM, Vogels CBF, Brackney DE, Casanovas-Massana A, Campbell M, Fournier J, Bermejo S, Datta R, Dela Cruz CS, Farhadian SF, Iwasaki A, Ko AI, Grubaugh ND, Wyllie AL, . Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples - Volume 27, Number 4—April 2021 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2021, 27: 1184-1187. PMID: 33755009, PMCID: PMC8007323, DOI: 10.3201/eid2704.204200.Peer-Reviewed Original Research